Clonality testing: telling lymphoma from a reactive response
- Topic
A normal immune response uses many different lymphocytes; a lymphoma is one lymphocyte copied over and over, and the lab can prove which it is.
What it is
Clonality tests ask whether a population of lymphocytes comes from many cells (polyclonal, usually reactive) or from one cell (monoclonal, suggesting a neoplasm). Flow cytometry looks for light-chain restriction and abnormal marker patterns, molecular tests look for a single rearranged immunoglobulin or T-cell receptor gene, and serum tests look for a monoclonal protein. Results are always read together with the morphology and the clinical picture.
Key facts
- Clonal expansions can occur in benign settings (some viral infections, ageing T cells, MGUS), so clonality alone is not cancer.
- Polyclonal hypergammaglobulinaemia suggests chronic infection, liver disease or autoimmunity; a monoclonal spike suggests a plasma-cell disorder.
- Next-generation sequencing of a clone’s receptor gene can track minimal residual disease after treatment.
Step by step
- An enlarged node or abnormal blood count raises the question of lymphoma or leukaemia.
- Tissue is obtained, ideally by excisional or core biopsy so the architecture can be seen.
- Flow cytometry checks κ:λ ratio of B cells and aberrant phenotypes (for example CD5 on B cells, loss of CD7 on T cells).
- Immunohistochemistry maps markers and architecture (CD20, CD3, CD10, BCL2, cyclin D1, Ki-67).
- PCR or sequencing of IGH or TCR genes looks for one dominant rearrangement.
- FISH or karyotype finds characteristic translocations (t(14;18), t(11;14), MYC).
- The pathologist integrates morphology, phenotype and molecular results into a diagnosis.
Clonality clues by method
| Method | Polyclonal (reactive) | Monoclonal (suspicious) |
|---|---|---|
| Flow cytometry (B cells) | Mixed κ and λ light chains | Only κ or only λ (light-chain restriction) |
| Flow cytometry (T cells) | Normal antigen pattern, mixed Vβ families | Loss of CD7 or other antigens, single Vβ family |
| PCR of IGH / TCR genes | Many sizes (smear or Gaussian curve) | One dominant peak or band |
| Serum protein electrophoresis and immunofixation | Broad polyclonal rise of gamma globulins | Narrow M spike of one heavy and one light chain |
| Serum free light chains | Normal κ/λ ratio | Abnormal κ/λ ratio |
Common traps
- A monoclonal result means cancer: small benign clones occur in MGUS, some infections and ageing, so clonality only supports a diagnosis read with morphology.
- A high κ:λ ratio means κ cells are healthy and dominant: either extreme ratio (only κ or only λ) is light-chain restriction and signals one clone.
- Polyclonal hypergammaglobulinaemia suggests myeloma: a broad gamma rise is reactive (infection, liver disease, autoimmunity), myeloma gives a narrow M spike.
- A fine-needle aspirate is enough to call lymphoma: architecture matters, so an excisional or core biopsy is preferred.
Test yourself
Think of the answer, then tap the question to see it.
Flow cytometry of a lymph node shows B cells that all express λ light chain. What does this mean and why?
Light-chain restriction: each B cell uses only κ or λ, so a population that is all λ came from one cell, a clonal (likely neoplastic) expansion.
Why does PCR of IGH genes give a smear in a reactive node but a single peak in lymphoma?
Each B clone has a different-length V(D)J junction; many clones give many sizes, one clone gives one dominant size.
An older adult has a small IgG-κ M spike, normal blood counts and no organ damage. Is this myeloma?
Not necessarily: a small clone without end-organ damage fits MGUS, which is monitored; clonality alone is not cancer.
Elsewhere in DurgiPedia
- Reactive lymphadenitis: the patterns
- Immunohistochemistry: the principle and the markers to know
- Plasma cell disorders: MGUS to myeloma
Connections
Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.
Sources: Immune response (MedlinePlus, US National Library of Medicine, 2024); ELISA blood test (MedlinePlus, US National Library of Medicine, 2024).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
